



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Compounds with general formula (I)



in which



m is the number 0 or 1;

Z and Z', which can be the same or different, are an integer ranging from 0 to 2;

Y and Y', which can be the same or different, are (CH₂)_{n₁}; (CH₂)_{n₂}-CH[NR^{VII}](CH₂)_{n₄}-NHR^I]- (CH₂)_{n₃}; CH₂-CH[CH₂-CH₂]₂- or (CH₂)_{n₂}-N[(CH₂)_{n₄}-NHR^{IV}]- (CH₂)_{n₃};

Y^{''} is selected from the group consisting of H; cycloalkyl C₃-C₇; (CH₂)_{n₅}-N[CH₂-CH₂]₂N-(CH₂)_{n₆}NHR^V; (CH₂)_{n₇}-CH[CH₂-CH₂]₂NR^V;

X is O, or is a simple bond;

n-n₈, which can be the same or different, are an integer ranging from 0 to 5;

R^I, R^{II}, R^{III}, R^{IV}, and R^V, which can be the same or different, are a protective group for the nitrogen to which they are bound; CO₂R^{VI}; CO₂CH₂Ar; CO₂(9-fluorenylmethyl); (CH₂)_{n₅}-NHCO₂R^{VI}; CH₂Ar; COAr; (CH₂)_{n₅}-NHCO₂CH₂Ar; (CH₂)_{n₅}-NHCO₂-(9-fluorenylmethyl).

R^{VI} is a straight or branched (C₁-C₆) alkyl;

R^{VII} is H or R^I-R^V;

Ar is a C₆-C₁₂ aromatic residue, such as phenyl, optionally substituted with one or more groups selected from: halogen, hydroxy, C₁-C₅ alkyl, C₁-C₅ alkoxy, phenyl, cyano, nitro, -NR^{VIII}R^{IX}, where R^{VIII} and R^{IX}, which can be the same or different, are hydrogen, straight or branched (C₁-C₅) alkyl, or Ar is a heterocyclic group, said heterocyclic group containing at least one heteroatom selected from a nitrogen atom, optionally substituted with a (C₁-C₅) alkyl group, and/or oxygen and/or sulphur; said heterocycle can be substituted with one or more groups selected from halogen, hydroxy, C₁-C₅ alkyl, C₁-C₅ alkoxy, phenyl, cyano, nitro, -NR^{VIII}R^{IX}, where R^{VIII} and R^{IX}, which can be the same or different, are hydrogen, straight or branched (C₁-C₅) alkyl, the N₁-oxides, racemic mixtures, their individual enantiomers, their individual diastereoisomers, the *E* and *Z* forms, their mixtures, and pharmaceutically acceptable salts.

2. (Original) Compounds according to claim 1, in which the protective groups are bulky groups of a lipophilic nature.

3. (Original) Compounds according to claim 1, in which the protective groups are selected from the group consisting of: $\text{CO}_2\text{R}^{\text{VI}}$; $\text{CO}_2\text{CH}_2\text{Ar}$; CO_2 -(9-fluorenylmethyl); $(\text{CH}_2)_n\text{-NHCO}_2\text{R}^{\text{VI}}$; $(\text{CH}_2)_n\text{-NHCO}_2\text{CH}_2\text{Ar}$; $(\text{CH}_2)_n\text{-NHCO}_2$ -(9-fluorenylmethyl), in which R^{VI} is as defined above.

4. (Original) Compounds according to claim 3, in which the protective groups are selected from the group consisting of tert-butoxycarbonyl; benzyloxycarbonyl; 9-fluorenylmethyloxycarbonyl.

5. (Currently Amended) Compounds according to ~~any of claims~~claim 1 ~~1~~ ~~[[4]]~~, in which m is 0.

6. (Original) Compounds according to claim 5, selected from the group consisting of:

- tert-butylester of 20S-(4-[[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino]-butyl)-(3-tert-butoxycarbonylamino-propyl)-carbamic acid;
- tert-butylester of 20S-(4-[[3-(7-camptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino]-butyl)-carbamic acid;
- tert-butylester of 20S-[3-(7-camptothecinylidene-amino)-butyl]-carbamic acid;
- 20S-7-[3-(N-tert-butoxycarbonylamino)propoxyimino-methyl]-camptothecin.

7. (Currently Amended) Compounds according to ~~any of claims~~claim 1~~[[4]]~~, in which m is 1.

8. (Original) Compounds according to claim 7, selected from the group consisting of:

- tert-butylester of 20RS-(4-([3-(7-homocamptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino)-butyl)-(3-tert-butoxycarbonylaminopropyl)-carbamic acid;
- tert-butylester of 20RS-(4-([3-(7-homocamptothecinylidene-amino)-propyl]-tert-butoxycarbonyl-amino)-butyl)-carbamic acid;
- tert-butylester of 20RS-[3-(7-homocamptothecinylidene-amino)-butyl]-carbamic acid;
- 20R,S-7-[3-(N-tert-butoxycarbonylaminopropoxyimino-methyl)-homocamptothecin

9. (Currently Amended) Pharmaceutical composition containing at least one compound according to ~~claims~~claim 1-8 as the active ingredient in admixture with at least one pharmaceutically acceptable vehicle and/or excipient.

10. (Currently Amended) Use of compounds according to ~~claims~~claim 1-8 as medicaments.

GIANNINI et al.

New National Phase Application Based on PCT/IT2004/000374

11. (Currently Amended) Use of compounds according to ~~claims~~claim 1-8 for the preparation of a medicament with topoisomerase 1 inhibiting activity.

12. (Original) Use according to claim 11 for the preparation of a medicament with anticancer activity.

13. (Original) Use according to claim 11 for the preparation of a medicament with antiparasite activity.

14. (Original) Use according to claim 11 for the preparation of a medicament with antiviral activity.